Tumor necrosis factor-alpha antibodies in fistulizing crohn's disease: An updated systematic review and meta-analysis
Medical treatment for fistulizing Crohn's disease (FCD) is changing rapidly over the time by the introduction of novel therapeutic medicines, while no global consensus is available. This study aims to accomplish a systematic review and meta-analysis on the efficacy of tumor necrosis factor-alph...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| Series: | Journal of Research in Pharmacy Practice |
| Subjects: | |
| Online Access: | http://www.jrpp.net/article.asp?issn=2319-9644;year=2017;volume=6;issue=3;spage=135;epage=144;aulast=Zaboli |
| _version_ | 1818570862813511680 |
|---|---|
| author | Pardis Zaboli Mohammad Abdollahi Shilan Mozaffari Shekoufeh Nikfar |
| author_facet | Pardis Zaboli Mohammad Abdollahi Shilan Mozaffari Shekoufeh Nikfar |
| author_sort | Pardis Zaboli |
| collection | DOAJ |
| description | Medical treatment for fistulizing Crohn's disease (FCD) is changing rapidly over the time by the introduction of novel therapeutic medicines, while no global consensus is available. This study aims to accomplish a systematic review and meta-analysis on the efficacy of tumor necrosis factor-alpha antibodies (anti-TNF-α antibodies) versus placebo in FCD. A systematic review of published literature was carried out till December 2016, and a meta-analysis of identified studies was done. Data have been explored from PubMed, Scopus, Cochrane Library Database, and Web of Science. Predefined exclusion criteria for included studies in meta-analysis are based on search methodology and are as follows: Randomized clinical trial about Crohn's disease (CD) patients without fistula, pediatrics CD, randomized clinical trials about pregnant women with FCD, nonhuman studies, randomized clinical trials with surgical therapies interventions, conference abstracts, case reports, and language other than English studies. All randomized placebo-controlled trials were included. To assess risk of bias, Jadad score was applied to evaluate trials' methodological quality. Relative risk (RR) and 95% confidence intervals were computed using Mantel-Haenszel and/or Rothman-Boice (for fixed effects) or Der Simonian-Laird (for random effects) techniques. Nine studies attained defined inclusion criteria. The meta-analysis results showed that anti-TNF-α antibodies are remarkably more effective in comparison to placebo for fistula closure maintenance (RR = 2.36; 95% confidence interval: 1.58–3.55; P < 0.0001) in patients with FCD, whereas anti-TNF-α antibodies were not superior to placebo neither in fistula improvement nor in fistula closure. We concluded that adalimumab and certolizumab pegol are both effective in fistula closure maintenance in adult patients with FCD. |
| first_indexed | 2024-12-14T13:47:32Z |
| format | Article |
| id | doaj.art-f1f1a5e219a04cb9a019778147886749 |
| institution | Directory Open Access Journal |
| issn | 2319-9644 2279-042X |
| language | English |
| last_indexed | 2024-12-14T13:47:32Z |
| publishDate | 2017-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Research in Pharmacy Practice |
| spelling | doaj.art-f1f1a5e219a04cb9a0197781478867492022-12-21T22:59:15ZengWolters Kluwer Medknow PublicationsJournal of Research in Pharmacy Practice2319-96442279-042X2017-01-016313514410.4103/jrpp.JRPP_17_46Tumor necrosis factor-alpha antibodies in fistulizing crohn's disease: An updated systematic review and meta-analysisPardis ZaboliMohammad AbdollahiShilan MozaffariShekoufeh NikfarMedical treatment for fistulizing Crohn's disease (FCD) is changing rapidly over the time by the introduction of novel therapeutic medicines, while no global consensus is available. This study aims to accomplish a systematic review and meta-analysis on the efficacy of tumor necrosis factor-alpha antibodies (anti-TNF-α antibodies) versus placebo in FCD. A systematic review of published literature was carried out till December 2016, and a meta-analysis of identified studies was done. Data have been explored from PubMed, Scopus, Cochrane Library Database, and Web of Science. Predefined exclusion criteria for included studies in meta-analysis are based on search methodology and are as follows: Randomized clinical trial about Crohn's disease (CD) patients without fistula, pediatrics CD, randomized clinical trials about pregnant women with FCD, nonhuman studies, randomized clinical trials with surgical therapies interventions, conference abstracts, case reports, and language other than English studies. All randomized placebo-controlled trials were included. To assess risk of bias, Jadad score was applied to evaluate trials' methodological quality. Relative risk (RR) and 95% confidence intervals were computed using Mantel-Haenszel and/or Rothman-Boice (for fixed effects) or Der Simonian-Laird (for random effects) techniques. Nine studies attained defined inclusion criteria. The meta-analysis results showed that anti-TNF-α antibodies are remarkably more effective in comparison to placebo for fistula closure maintenance (RR = 2.36; 95% confidence interval: 1.58–3.55; P < 0.0001) in patients with FCD, whereas anti-TNF-α antibodies were not superior to placebo neither in fistula improvement nor in fistula closure. We concluded that adalimumab and certolizumab pegol are both effective in fistula closure maintenance in adult patients with FCD.http://www.jrpp.net/article.asp?issn=2319-9644;year=2017;volume=6;issue=3;spage=135;epage=144;aulast=ZaboliFistulizing Crohn's diseasemeta-analysistumor necrosis factor-α antibodies |
| spellingShingle | Pardis Zaboli Mohammad Abdollahi Shilan Mozaffari Shekoufeh Nikfar Tumor necrosis factor-alpha antibodies in fistulizing crohn's disease: An updated systematic review and meta-analysis Journal of Research in Pharmacy Practice Fistulizing Crohn's disease meta-analysis tumor necrosis factor-α antibodies |
| title | Tumor necrosis factor-alpha antibodies in fistulizing crohn's disease: An updated systematic review and meta-analysis |
| title_full | Tumor necrosis factor-alpha antibodies in fistulizing crohn's disease: An updated systematic review and meta-analysis |
| title_fullStr | Tumor necrosis factor-alpha antibodies in fistulizing crohn's disease: An updated systematic review and meta-analysis |
| title_full_unstemmed | Tumor necrosis factor-alpha antibodies in fistulizing crohn's disease: An updated systematic review and meta-analysis |
| title_short | Tumor necrosis factor-alpha antibodies in fistulizing crohn's disease: An updated systematic review and meta-analysis |
| title_sort | tumor necrosis factor alpha antibodies in fistulizing crohn s disease an updated systematic review and meta analysis |
| topic | Fistulizing Crohn's disease meta-analysis tumor necrosis factor-α antibodies |
| url | http://www.jrpp.net/article.asp?issn=2319-9644;year=2017;volume=6;issue=3;spage=135;epage=144;aulast=Zaboli |
| work_keys_str_mv | AT pardiszaboli tumornecrosisfactoralphaantibodiesinfistulizingcrohnsdiseaseanupdatedsystematicreviewandmetaanalysis AT mohammadabdollahi tumornecrosisfactoralphaantibodiesinfistulizingcrohnsdiseaseanupdatedsystematicreviewandmetaanalysis AT shilanmozaffari tumornecrosisfactoralphaantibodiesinfistulizingcrohnsdiseaseanupdatedsystematicreviewandmetaanalysis AT shekoufehnikfar tumornecrosisfactoralphaantibodiesinfistulizingcrohnsdiseaseanupdatedsystematicreviewandmetaanalysis |